CYP2D6 genotyping combined with the unique spectrum of BRCA1/2 founder mutations identified in the South African population [29,30], forms part of the pathology-supported pharmacogenetics test developed by van der Merwe [31] for improved clinical management of patients with breast cancer and associated comorbidities. Here, CYP2D6 is linked to breast carcinoma.